To determine whether NVB would activate the cGAS/STING pathway in HR-deficient cancers in vivo, we performed flow cytometric analysis of both Brca1-deficient TNBC tumors and Brca2-deficient PDAC tumors from immunocompetent mice treated for 5 days with NVB. The gene discussed is BRCA2; the disease is cancer.